Trial Profile
A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Nivolumab (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 23 Jul 2020 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Initial safety and efficacy results (n=68) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 31 Jan 2018 Planned number of patients changed from 60 to 95.